CBL International Limited filed a current report with the SEC on November 16, 2026, disclosing the appointment of Privatco CPA Limited as its independent registered public accounting firm and the simultaneous dismissal of MRI Moores Rowland LLP, both effective November 13, 2026.
InspireMD, Inc. filed a Form 8-K on November 16, 2026, disclosing an underwriting agreement dated November 13, 2026, for an underwritten public offering expected to raise approximately $37.5 million in gross proceeds.
Huadi International Group Co., Ltd. filed a Form 6-K on November 16, 2026, reporting the results of an extraordinary general meeting of shareholders held that same day, at which shareholders approved a share consolidation, a par value reduction, and an authorized share capital increase.
Golden Sun Technology Group Limited filed a Form 6-K on November 16, 2026, disclosing its election to rely on certain home country corporate governance exemptions available to foreign private issuers under Nasdaq Listing Rule 5615.
AstraZeneca PLC filed a Form 6-K on 16 November 2026 disclosing that the US Food and Drug Administration approved Klygefa (gefurulimab) for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
Evogene Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 16, 2026, disclosing the resignation of Nir Nimrodi as chairman and member of the board of directors, effective November 13, 2026.
Nixxy, Inc. filed its Form 10-Q with the SEC on November 16, 2026, covering the quarterly period ended September 30, 2026, reporting condensed consolidated financial results for the three and nine months ended on that date.
AstraZeneca PLC filed a Form 6-K on 16 November 2026 disclosing that the U.S. Food and Drug Administration approved Imfinzi (durvalumab) in combination with enfortumab vedotin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy, for adult patients with muscle-invasive …
Invivyd, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 16, 2026, reporting financial results for the three and nine months ended that date.
Duke Robotics Corp. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 16, 2026, disclosing revenue growth alongside a significantly expanded accumulated deficit and a substantial increase in stockholders' equity following new capital raises.